Evotec and Novo Nordisk Enter Partnership for Next-Generation Cell Therapies

Evotec SE and Novo Nordisk have announced a technology development partnership aimed at advancing stem cell-based therapies. The collaboration focuses on developing off-the-shelf cell therapy products, addressing both clinical and commercial needs.

Under the agreement, Novo Nordisk will fund technology development at Evotec’s R&D site in Göttingen, Germany, and its cell therapy manufacturing facility in Modena, Italy. Novo Nordisk may obtain exclusive rights for using the results in a specific therapeutic area, while Evotec will receive funding and potential milestone and royalty payments.

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the promise of stem cell-based therapies in becoming functional cures. Meanwhile, Dr. Joachim Fruebis, Corporate Vice President at Novo Nordisk, highlighted the partnership's potential for significant advancements in cell therapies.